The therapeutic effect of concurrent administration of 5-fluorouracil and allylestrenol or hexestrol in small doses on prostatic carcinoma.
A trial to reduce the dosage of estrogen or to substitute it by other agents was done as a treatment of prostatic carcinoma. Either the combination of 5-FU (200 mg/day) and allylestrenol (50 mg/day), or 5-FU and hexestrol (20 mg/day) was given to 24 cases of prostatic carcinoma, 4 of whom were relapsed hormonal-resistant cases, 14 cases were controlled by large doses of estrogen and 6 were newly treated cases. No progressions were observed following 3 months of therapy. In 5 cases, progression was observed after 6 months. Deteriorated cases increased to 6 cases after 12 months. The effective rate, according to the "vital score," which is proposed as a parameter of the physical condition of patients with prostatic carcinoma, was calculated to be 100% at 3 months, 77% at 6 months, and 71% at 12 months.
D000368:Aged; D000500:Allylestrenol / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004963:Estrenes / Q000008:administration & dosage*; D005472:Fluorouracil / Q000008:administration & dosage*; D006589:Hexestrol / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004963:Estrenes; D006589:Hexestrol; D000500:Allylestrenol; D005472:Fluorouracil